Researchers sceptical about J&J jab’s ability to guard against Delta

They say it produced lower levels of antibodies against the strain compared with others, but J&J disputes this

21 July 2021 - 19:33 By Robert Langreth

Johnson & Johnson’s (J&J) single-dose Covid-19 vaccine produced relatively low levels of antibodies against the Delta variant in a study, raising questions about how well the shot will hold up against the strain that accounts for the vast majority of new cases around the world.

The laboratory study, released on the preprint server bioRxiv, hasn’t been published in a peer-reviewed journal and focuses on one key portion of the immune response, called neutralising antibodies. New York University (NYU) scientists found J&J’s vaccine produced roughly five-fold lower levels of the protective antibodies against the Delta variant compared with levels raised against an early coronavirus strain...

This article is free to read if you register or sign in.

If you have already registered or subscribed, please sign in to continue.

Questions or problems? Email or call 0860 52 52 00.